Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$72.79 – $92.60
80% from low
Exchange
ARCX
ETF
Borrow rate
0.41%
Easy to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AVDEAvantis International Equity ETF | $88.61 | +0.01% | $17.0B | — |
| AVDVAvantis International Small Cap Value ETF | $102.97 | -0.80% | $18.5B | — |
| AVUSAvantis U.S. Equity ETF | $126.52 | +0.34% | $13.3B | — |
| DFAUDimensional - US Core Equity Market ETF | $51.02 | +0.55% | $12.2B | — |
| DFAXDimensional World ex U.S. Core Equity 2 ETF |
No company description on file.
No one on the platform currently holds AVDE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 25,900 | $2.2M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-09 | $1.1657 | 2026-06-11 |
| 2026-03-10 | $0.0972 | 2026-03-12 |
| 2025-12-16 | $0.9433 | 2025-12-18 |
| 2025-06-24 | $1.2479 | 2025-06-26 |
| 2024-12-17 | $0.8501 | 2024-12-19 |
| 2024-06-24 | $1.1718 | 2024-06-26 |
| 2023-12-18 | $0.7718 | 2023-12-21 |
No one on the platform has traded AVDE yet.
| $36.37 |
| -0.15% |
| $12.1B |
| — |
| DFICDimensional - International Core Equity 2 ETF | $37.02 | -0.01% | $14.3B | — |
| DUHPDimensional - US High Profitability ETF | $41.28 | +0.82% | $12.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$QQQ $QLD $AVDE also took some profits from international yesterday. Overall tactical $$ will come in handy and imo sooner than later as this market does its spinning top candle and most people don’t realize we actually have bearish divergences on indices
View on StockTwits ↗AZN Stock Rise As Wall Street Dismisses FDA Committee’s Rejection Of Breast Cancer Drug $AZN $PVAL $AVDE https://stocktwits.com/news/equity/markets/azn-stock-rise-as-wall-street-dismisses-fda-commitees-rejection-of-breast-cancer-drug/cZBMnogReIf
View on StockTwits ↗BP Stock Jumps Over 3% Premarket: US-Iran War Drives Best Quarter In Years $BP $DFIV $AVDE https://stocktwits.com/news/equity/markets/bp-stock-jumps-premarket-us-iran-war-drives-best-quarter-in-years/cZB8oU3Re5j
View on StockTwits ↗GSK Reportedly Pulls Application For Drug Touted By Trump As Potential Treatment For Autism $GSK $AVDE $FENI https://stocktwits.com/news/equity/markets/gsk-reportedly-pulls-application-for-drug-touted-by-trump-as-potential-treatment-for-autism/cZJWiLwRIs1
View on StockTwits ↗Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’ $NVO $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-launches-higher-dose-of-wegovy-injection-across-us/cZJJyAuRIpU
View on StockTwits ↗Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock $NVO $HIMS $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-hims-deal-turns-wall-street-bullish-hims-stock-upgrades/cZdos7IRI7d
View on StockTwits ↗HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy $HIMS $NVO $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk
View on StockTwits ↗Why Is NVO Stock Falling Pre-Market Today? $NVO $PPH $PVAL $AVDE $FTHI https://stocktwits.com/news/equity/markets/why-is-nvo-stock-falling-pre-market-today/cZRtZlKR4UC
View on StockTwits ↗Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly $NVO $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-reportedly-eyes-launching-wegovy-in-vials/cZb6rpcR4A0
View on StockTwits ↗$AVDE Current Stock Price: $90.68 Contracts to trade: $85.0 AVDE Feb 20 2026 Call Entry: $4.00 Exit: $6.47 ROI: 62% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains $NVO $HIMS $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/fda-novo-wegovy-pill-tv-advertisement-misleading-nvo-stock-pares-gains/cZbv5uwR4oX
View on StockTwits ↗Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks $NVO $HIMS $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2
View on StockTwits ↗$AVDE Market participants want evidence that strategy converts to numbers; competitive differentiation has to emerge in data — discipline in guidance could rebuild trust. Until validation appears, volatility remains the default.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.